Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CM326 in Healthy Subjects
NCT05715333Phase 1Completed
- Sponsor
- Keymed Biosciences
- Start
- Mar 2023
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CM326 in asthma, atopic dermatitis (AD) and chronic rhinosinusitis with nasal polyps (CRSwNP) (4 arms), sponsored by Keymed Biosciences. Primary endpoint: Emergency adverse events during treatment at 12 weeks. Started Mar 2023; status: completed.
02
Drugs
CM326
03
Conditions
asthmaatopic dermatitis (AD)chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT05715333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05715333.